Cargando…

2493. Real-World Utilization of Ibalizumab (IBA) Without an Optimized Background Regimen (OBT)

BACKGROUND: It is difficult to treat multidrug-resistant (MDR) human immunodeficiency virus (HIV). Trogarzo® (ibalizumab) a novel monoclonal antibody was approved in 2018 for heavily treatment-experienced HIV patients. Data support IBA use with at least one fully active agent, an OBR. Real-world IBA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchard, Jeannette, Derrick, Caroline, Horvath, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809681/
http://dx.doi.org/10.1093/ofid/ofz360.2171